NCT06800651 Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
| NCT ID | NCT06800651 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Jemincare |
| Condition | ADPKD (Autosomal Dominant Polycystic Kidney Disease) |
| Study Type | INTERVENTIONAL |
| Enrollment | 135 participants |
| Start Date | 2025-03-13 |
| Primary Completion | 2027-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 135 participants in total. It began in 2025-03-13 with a primary completion date of 2027-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Eligibility Criteria
Inclusion Criteria: * Able to understand the procedures of this trial and provide written informed consent voluntarily; * Age between 18 to 55 years, male or female; * ADPKD diagnostic criteria were met before randomization; * Rapidly progressive ADPKD criteria were met. Exclusion Criteria: * 12 weeks prior to screening, patients had taken tolvaptan or another ADPKD improvers, or patients who were assessed by the investigator to be likely to use diuretic during the trial period; * Praticipants who are unable to feel thirst, or have difficulty with fluid/food intake; * Patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the ICF; * The investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.
Contact & Investigator
Hong Zhang, Ph.D
STUDY CHAIR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT06800651 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying ADPKD (Autosomal Dominant Polycystic Kidney Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06800651 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06800651 currently recruiting?
Yes, NCT06800651 is actively recruiting participants. Contact the research team at zhouxiaojun@jemincare.com for enrollment information.
Where is the NCT06800651 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06800651 clinical trial?
NCT06800651 is sponsored by Jemincare. The principal investigator is Hong Zhang, Ph.D at Peking University First Hospital. The trial plans to enroll 135 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.